Efficacy of bevacizumab combined with taxane drug in treating advanced human epidermal growth factor receptor-2 negative breast cancer
10.3760/cma.j.cn101721-20240402-00103
- VernacularTitle:贝伐珠单抗联合紫杉类药物治疗晚期人表皮生长因子受体2阴性乳腺癌患者的效果观察
- Author:
Yan ZHAO
1
;
Yue ZHU
;
Xiu WANG
;
Jun LIU
Author Information
1. 四川绵阳四〇四医院 绵阳市第一人民医院乳腺外科，绵阳 621000
- Keywords:
Bevacizumab;
Taxane drug;
Human epidermal growth factor receptor 2;
Breast cancer;
Tumor markers;
Prognosis
- From:
Clinical Medicine of China
2024;40(4):291-297
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect of bevacizumab combined with taxanes in the treatment of advanced human epidermal growth factor receptor-2 (HER-2) negative breast cancer.Method:A total of 61 patients with advanced HER-2 negative breast cancer admitted to SiChuan Mianyang 404 Hospital from January 2021 to June 2023 were selected as the research objects, giving one to paclitaxel (albumin combined type) treatment of 29 patients in control group, will be cut bead single combined therapy with paclitaxel (albumin combined type) of 32 patients into the observation group. The clinical efficacy (objective response rate (ORR) and disease control rate (DCR)), the levels of tumor markers (carcinoembryonic antigen (CEA) and carbohydrate antigen 125 (carbohydrate)) before and after treatment were compared between the two groups CA125, carbohydrate antigen 153 (CA153), adverse reactions during treatment; Measurement data with normal distribution were represented as indicated, and comparison between groups was analyzed using the t test. Rate between group compared with chi-square test. The rank sum test was used to compare the constituent ratio of ordinal data between groups. Kaplan-Meier survival curve was used to analyze the prognosis of patients. Results After treatment, the ORR and DCR of the observation group were significantly higher than those of the control group (53.13%(17/32) vs 27.59 (8/29), 84.38% (27/32) vs 62.07% (18/29)), the differences were statistically significant ( χ2=4.10, 3.91, all P<0.05). After treatment, the serum CEA, CA125 and CA153 in the observation group were significantly lower than those in the control group (CEA: (15.76±1.89) ng/mL vs. (20.24±2.36) ng/mL, CA125: (25.78±3.44) kU/L vs (34.66±4.01) kU/L, CA125: (25.78±3.44) kU/L vs. (34.66±4.01) kU/L; CA153: (18.34±2.19) kU/L vs. (24.19±3.28) kU/L). The difference between the two groups was statistically significant ( t-values were 8.22, 9.31, and 8.26, all P<0.01). There was no significant difference in the incidence of adverse reactions between the two groups during treatment ( P>0.05). The median progression-free survival (PFS) of the observation group was significantly longer than that of the control group (8 months vs 5 months, χ2=7.14, P=0.008). Conclusions:Bevacizumab combined with taxanes in the treatment of patients with advanced HER-2 negative breast cancer has definite short-term efficacy, can inhibit the expression of tumor markers, prolong PFS, has good safety, and is worthy of clinical application.
